ERBB2 and gastric cancer: In HER2-positive GC, fructose-6-phospho-kinase 2 activates the glycolytic pathway, contributing to the development of trastuzumab resistance Targeting PFKFB3 (a key enzyme for glycolysis) can increase sensitivity to anti-HER2 therapy (185).